A groundbreaking study presented at the American Society of Nephrology Kidney Week 2025 has revealed a potential breakthrough in treating Focal Segmental Glomerulosclerosis (FSGS). The research, led by Dr. Nicholas Cross, highlights a novel approach targeting podocytes, specialized cells in the kidneys, to combat a devastating condition.
FSGS is a severe kidney disease that affects about half of patients presenting with proteinuria, leading to kidney failure within a decade. The decline is closely linked to the overactivity of the transient receptor potential cation channel, subfamily-C, member-6 (TRPC6), which disrupts podocyte function and worsens kidney health. This discovery is particularly significant as inherited mutations in TRPC6 can cause genetic FSGS, making it a promising therapeutic target.
The study, titled 'TRPC6 Inhibition for the Treatment of FSGS: Phase 2 Randomized Controlled Trial of BI 764198,' focused on an oral selective TRPC6 inhibitor called BI 764198. The primary goal was to assess its effectiveness in reducing proteinuria, a key indicator of kidney damage. Participants with primary or genetic FSGS and known TRPC6 mutations were randomly assigned to receive different doses of BI 764198 or a placebo.
The results were impressive. Patients receiving 20 mg of BI 764198 showed a 44% improvement in proteinuria reduction at week 12, compared to 7% in the placebo group. This trend continued with higher doses, where 80 mg achieved a 43% improvement. In patients with TRPC6 mutations, the success rate was even higher, with 100% achieving a proteinuria response.
Importantly, BI 764198 demonstrated its safety and tolerability, with no significant differences in adverse event frequencies across treatment arms. The researchers concluded that this podocyte-targeted therapy is a promising step forward in FSGS treatment, offering hope to patients suffering from this debilitating condition.
The study was funded by Boehringer Ingelheim, and the findings were presented as an abstract at the American Society of Nephrology Kidney Week 2025, with the reference number SA-OR046. This research opens up exciting possibilities for personalized medicine in kidney health, inviting further exploration and discussion in the medical community.
